0001651944-23-000074.txt : 20230803 0001651944-23-000074.hdr.sgml : 20230803 20230803160730 ACCESSION NUMBER: 0001651944-23-000074 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230803 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230803 DATE AS OF CHANGE: 20230803 FILER: COMPANY DATA: COMPANY CONFORMED NAME: DermTech, Inc. CENTRAL INDEX KEY: 0001651944 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 842870849 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38118 FILM NUMBER: 231139925 BUSINESS ADDRESS: STREET 1: 12340 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 BUSINESS PHONE: 858-450-4222 MAIL ADDRESS: STREET 1: 12340 EL CAMINO REAL CITY: SAN DIEGO STATE: CA ZIP: 92130 FORMER COMPANY: FORMER CONFORMED NAME: Constellation Alpha Capital Corp. DATE OF NAME CHANGE: 20150827 8-K 1 dmtk-20230803.htm 8-K dmtk-20230803

Washington, D.C. 20549
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 3, 2023
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
of incorporation)
File Number)
(IRS Employer
Identification No.)
12340 El Camino Real
San DiegoCA 92130
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code (858450-4222
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock,
par value $0.0001 per share
DMTK Nasdaq
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02.    Results of Operations and Financial Condition.
On August 3, 2023, the Company issued a press release announcing its financial results for the quarter ended June 30, 2023 and certain other information. This press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information set forth under this Item 2.02 and in Exhibit 99.1 is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section. The information contained herein and in the accompanying exhibit is not to be incorporated by reference in any filing of the Company under the Exchange Act or the Securities Act of 1933, as amended, whether made before or after the date hereof and irrespective of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such a filing.
Item 9.01.    Financial Statements and Exhibits.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: August 3, 2023
By:/s/ Kevin Sun
Name:Kevin Sun
Title:Chief Financial Officer

EX-99.1 2 dmtk-2023q2earnings8xkxexx.htm EX-99.1 Document
Exhibit 99.1


-Covered lives increased to 133 million
-Average selling price and test revenue grew sequentially
-Cash runway into the first quarter of 2025

SAN DIEGO – August 3, 2023 – DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a leader in precision dermatology enabled by a non-invasive skin genomics technology, today reported its second-quarter 2023 financial results.

“We’ve recently taken a few necessary steps to streamline operations and put all our energy into scaling the DermTech Melanoma Test (DMT) and prioritizing reimbursed billable samples to grow revenue,” said Bret Christensen, CEO, DermTech. “We’re pursuing a large addressable market where significant patient need exists, with approximately 200,000 new cases of melanoma reported every year in the U.S. resulting in $3.3 billion in annual treatment costs. My vision is for the DMT to be deployed universally as part of the melanoma care pathway and we have an excellent product to execute against this goal.”

Christensen continued, “We’ve made solid progress in the first half of 2023 entering into new payer agreements. Since the end of last year, we’ve expanded covered lives approximately 45 percent to 133 million and now work with seven of the top ten Blues plans and two large governmental payers. We must continue to actively engage with payers and reinforce our message around the clinical and health economic benefits of our test, as well as improve the onboarding process once we’ve completed agreements. We’ve also begun to adjust our commercial tactics to support our focus on reimbursed tests and maximizing revenue. Importantly, we’ve modified incentive compensation for our sales team to prioritize revenue over volume and dissolved or merged certain sales territories to focus on geographies where we have broad insurance coverage. We’re also targeting our spending more closely to sales team enablement rather than broad-based marketing efforts. We need to build DMT adoption at the ground level with clinicians and are confident this change in our approach will be beneficial.”

Christensen concluded, “We believe anchoring our effort around monetizing our already significant demand is the best way to reach a meaningful revenue inflection point while managing our cash runway. We plan for revenue to grow in 2023, and as result of our recent restructuring actions, anticipate that our cash runway will now take us into the first quarter of 2025.”

Second-Quarter 2023 Financial Results
Billable sample volume declined 5 percent from the second quarter of 2022 to approximately 17,450.
Test revenue was $3.6 million, down 14 percent from the second quarter of 2022, primarily due to changes in collection estimates for tests run in prior periods and lower billable sample volume.
Total revenue was $4.0 million, a 6 percent decrease from the second quarter of 2022, driven by lower test revenue.
Cost of test revenue was $3.9 million, a 21 percent increase from the second quarter of 2022, yielding a test gross margin of negative 10 percent, compared to 22 percent for the second quarter of 2022. Cost of test revenue increased primarily because of higher infrastructure costs related to the Company’s new facility and higher materials expense.
Sales and marketing expenses were $13.0 million, a 13 percent decrease from the second quarter of 2022. The decrease was primarily attributable to lower marketing expenditures.
Research and development expenses were $3.9 million, a 44 percent decrease from the second quarter of 2022, largely due to lower employee-related and clinical study costs.
General and administrative expenses were $15.2 million, a $6.3 million or 71 percent increase from the second quarter of 2022. The increase was driven by approximately $2.9 million in additional non-cash stock-based compensation expense and $0.5 million in severance costs related to the former CEO’s departure, approximately $2.1 million of non-recurring restructuring costs and approximately $1.2 million of increased infrastructure costs related to the Company’s new facility.
Net loss was $31.4 million, or ($0.99) per share, which included $7.5 million of non-cash stock-based compensation expense, as compared to $29.6 million, or ($0.99) per share, for the second quarter of 2022, which included $4.8 million of non-cash stock-based compensation expense.
Cash, cash equivalents, restricted cash and short-term marketable securities were $89.7 million as of June 30, 2023. During the second quarter, the Company generated net proceeds of approximately $4.5 million from the issuance of 1,759,210 shares of common stock in at-the-market (ATM) offerings at a weighted average price of $2.62 per share. DermTech believes it has sufficient cash resources to fund its planned operations into the first quarter of 2025.

Conference Call Information
As previously announced, the Company will host a conference call to discuss its results at 5:00 p.m. ET on Thursday, August 3, 2023. For participants interested in asking questions during the teleconference, please register. After registering for the event, a confirmation e-mail will be sent with a meeting invitation and access information. Registration is open during the live teleconference, but advance registration is advised. For participants interested in listening only, please register for the webcast. For those unable to participate in the live call and webcast, a webcast replay will be available on the Company’s website shortly after the conclusion of the call.
About DermTech

DermTech is a leading genomics company in dermatology and is creating a new category of medicine, precision dermatology, enabled by its non-invasive skin genomics technology. DermTech’s mission is to improve the lives of millions by providing non-invasive precision dermatology solutions that enable individualized care. DermTech provides genomic analysis of skin samples collected non-invasively using our Smart StickersTM. DermTech markets and develops products that facilitate the early detection of skin cancers. For additional information, please visit www.dermtech.com.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. The expectations, estimates, and projections of DermTech may differ from its actual results and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” "outlook," “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believe,” “predict,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, expectations and evaluations with respect to: the performance, patient benefits, cost- effectiveness, commercialization and adoption of DermTech’s products and the market opportunity for these products, DermTech’s positioning and potential growth, financial outlook and future financial performance, ability to increase its proportion of reimbursed billable samples, ability to maintain or improve its operating efficiency and reduce operating expenses, the sufficiency of DermTech’s cash resources and runway and ability to access capital to fund its operating plan, the sufficiency of its cash resources to fund planned operations for the anticipated period, anticipated annual cash savings to be realized from the restructuring, implications and interpretations of any study results, and expectations regarding agreements with or reimbursement or cash collection patterns from government payers (including Medicare) or commercial payers and related billing practices or number of covered lives. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the control of DermTech and are difficult to predict. Factors that may cause such differences include, but are not limited to: (1) the outcome of any legal proceedings that may be instituted against DermTech; (2) DermTech’s ability to obtain additional funding to develop and market its products; (3) the existence of favorable or unfavorable clinical guidelines for DermTech’s tests; (4) the reimbursement of DermTech’s tests by government payers (including Medicare) and commercial payers; (5) the ability of patients or healthcare providers to obtain coverage of or sufficient reimbursement for DermTech’s products; (6) DermTech’s ability to grow, manage growth and retain its key employees and maintain or improve its operating efficiency and reduce operating expenses; (7) changes in applicable laws or regulations; (8) the market adoption and demand for DermTech’s products and services together with the possibility that DermTech may be adversely affected by other economic, business, and/or competitive factors; and (9) other risks and uncertainties included in the “Risk Factors” section of the most recent Annual Report on Form 10-K filed by DermTech with the Securities and Exchange Commission (the “SEC”), and other documents filed or to be filed by DermTech with the SEC, including subsequently filed reports. DermTech cautions that the foregoing list of factors is not exclusive. You should not place undue reliance upon any forward- looking statements, which speak only as of the date made. DermTech does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based.
Steve Kunszabo
(858) 291-1647

Condensed Consolidated Statements of Operations
(in thousands, except share and per share data)
Three Months Ended June 30,Six Months Ended June 30,
Test revenue $3,565 $4,147 $6,990 $7,665 
Contract revenue415 86 467 286 
Total revenues3,980 4,233 7,457 7,951 
Cost of revenues:    
Cost of test revenue3,909 3,236 7,700 6,766 
Cost of contract revenue63 37 93 61 
Total cost of revenues3,972 3,273 7,793 6,827 
Gross profit/(loss)960 (336)1,124 
Operating expenses:    
Sales and marketing13,033 15,001 28,450 30,444 
Research and development3,887 6,915 8,296 13,253 
General and administrative15,220 8,878 27,095 17,452 
Total operating expenses32,140 30,794 63,841 61,149 
Loss from operations(32,132)(29,834)(64,177)(60,025)
Other income/(expense):    
Interest income, net763 149 1,545 215 
Change in fair value of warrant liability105 (1)122 
Total other income769 254 1,544 337 
Net loss$(31,363)$(29,580)$(62,633)$(59,688)
Weighted average shares outstanding used in computing net loss per share, basic and diluted31,791,736 29,964,849 31,177,886 29,904,972 
Net loss per share of common stock outstanding, basic and diluted$(0.99)$(0.99)$(2.01)$(2.00)

Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
June 30, 2023December 31, 2022
Current assets:
Cash and cash equivalents$42,790 $77,757 
Short-term marketable securities43,406 48,411 
Accounts receivable3,865 4,172 
Inventory1,352 1,757 
Prepaid expenses and other current assets2,329 3,940 
Total current assets93,742 136,037 
Property and equipment, net6,074 6,375 
Operating lease right-of-use assets53,791 56,007 
Restricted cash3,467 3,488 
Other assets— 168 
Total assets$157,074 $202,075 
Liabilities and Stockholders’ Equity  
Current liabilities:  
Accounts payable$2,324 $2,419 
Accrued compensation7,387 7,894 
Accrued liabilities3,695 3,464 
Short-term deferred revenue295 109 
Current portion of operating lease liabilities2,246 1,634 
Current portion of finance lease obligations67 116 
Total current liabilities16,014 15,636 
Warrant liability
Long-term finance lease obligations, less current portion46 53 
Operating lease liabilities, long-term52,931 54,028 
Total liabilities68,997 69,722 
Stockholders’ equity:  
Common stock, $0.0001 par value per share; 100,000,000 shares authorized as of June 30, 2023 and December 31, 2022; 33,408,810 and 30,297,408 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively
Additional paid-in capital473,855 456,171 
Accumulated other comprehensive loss(101)(774)
Accumulated deficit(385,680)(323,047)
Total stockholders’ equity88,077 132,353 
Total liabilities and stockholders’ equity$157,074 $202,075 

EX-101.SCH 3 dmtk-20230803.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 dmtk-20230803_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 5 dmtk-20230803_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 screenshot2022-07x07150100a.jpg begin 644 screenshot2022-07x07150100a.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover Page
Aug. 03, 2023
Nov. 03, 2022
Cover [Abstract]    
Document Type 8-K  
Document Period End Date Aug. 03, 2023  
Entity Registrant Name DERMTECH, INC.  
Entity Incorporation, State or Country Code DE  
Entity File Number 001-38118  
Entity Tax Identification Number 84-2870849  
Entity Address, Address Line One 12340 El Camino Real
Entity Address, City or Town San Diego  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 92130  
City Area Code 858  
Local Phone Number 450-4222  
Written Communications false  
Soliciting Material false  
Pre-commencement Tender Offer false  
Pre-commencement Issuer Tender Offer false  
Title of 12(b) Security Common Stock,par value $0.0001 per share  
Trading Symbol DMTK  
Security Exchange Name NASDAQ  
Entity Emerging Growth Company false  
Amendment Flag false  
Entity Central Index Key 0001651944  
XML 8 dmtk-20230803_htm.xml IDEA: XBRL DOCUMENT 0001651944 2023-08-03 2023-08-03 0001651944 2022-11-03 2022-11-03 false 0001651944 8-K 2023-08-03 DERMTECH, INC. DE 001-38118 84-2870849 12340 El Camino Real San Diego CA 92130 858 450-4222 false false false false Common Stock,par value $0.0001 per share DMTK NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

@/ !?&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " #O@ -799!YDAD! #/ P $P M @ $:$P 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) + #X" !D% ! end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 2 22 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://dermtech.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports dmtk-20230803.htm dmtk-20230803.xsd dmtk-20230803_lab.xml dmtk-20230803_pre.xml dmtk-2023q2earnings8xkxexx.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "dmtk-20230803.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "contextCount": 2, "dts": { "inline": { "local": [ "dmtk-20230803.htm" ] }, "labelLink": { "local": [ "dmtk-20230803_lab.xml" ] }, "presentationLink": { "local": [ "dmtk-20230803_pre.xml" ] }, "schema": { "local": [ "dmtk-20230803.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "dmtk", "nsuri": "http://dermtech.com/20230803", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20230803.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page", "menuCat": "Cover", "order": "1", "role": "http://dermtech.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "dmtk-20230803.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://dermtech.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001651944-23-000074-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001651944-23-000074-xbrl.zip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end